DEF: Neumora Therapeutics 2026 Annual Meeting Proxy Statement

Neumora Therapeutics has issued its 2026 proxy statement detailing the upcoming annual meeting of stockholders scheduled for May 27, 2026.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on May 27, 2026, at 4:00 p.m. Eastern Time.
• Stockholders will vote on the election of three Class III directors: Paul L. Berns, Matthew Fust, and David Piacquad.
• The Audit Committee has appointed Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• The company is seeking a non-binding advisory vote on executive compensation and a non-binding advisory vote on the frequency of future executive compensation votes.
• The Board recommends a frequency of 'ONE YEAR' for future advisory votes on executive compensation.
• As of the April 7, 2026 record date, there were 182,688,076 shares of common stock outstanding.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a standard administrative proxy filing with no major strategic shifts or controversial proposals.

Positives

• The company maintains a Clawback Policy effective since September 14, 2023, to recover erroneously awarded compensation.
• The Board has adopted an Insider Trading Compliance Policy that prohibits hedging, pledging, and short sales of company securities by directors and officers.
• The Audit Committee has confirmed the independence of Ernst & Young LLP.
• The company has established clear procedures for stockholder communication with the Board.

Negatives

• The company reported a net loss for the fiscal years 2024 and 2025.
• The company experienced a leadership transition in February 2025, with Henry Gosebruch ceasing to serve as President and CEO.
• The company is a smaller reporting company, which limits certain disclosure requirements regarding executive compensation.

Risks

• The company is subject to risks associated with the development and regulatory approval of its product candidates, specifically navacaprant and NMRA-511.
• The company is dependent on its collaboration agreements, including those with Amgen, which involve significant milestone payments.
• The company faces potential risks related to the retention of key personnel and the successful execution of its clinical trials.

Future Outlook

The company continues to focus on its clinical development programs, specifically the Phase 3 clinical trial for navacaprant, and maintains its collaboration agreements to support long-term value creation.

Management Comments

• The Board believes that holding a vote every year is the most appropriate option because it will enable stockholders to express annually their views on our executive compensation program.
• The Board and Compensation Committee value the opinions expressed by stockholders in their vote on this proposal and will consider the outcome of the vote when making future compensation decisions.

Industry Context

StockSavvy.ai notes that Neumora's governance structure and reliance on venture-backed board representation are consistent with early-to-mid-stage biotechnology companies transitioning toward commercialization.

Comparison to Industry Standards

• The company's use of a staggered board is common among biotechnology firms to ensure continuity.
• The executive compensation structure, including sign-on bonuses and equity-based incentives, aligns with industry standards for attracting talent in the competitive biotech sector.
• The reliance on major pharmaceutical partners like Amgen for R&D collaboration is a standard de-risking strategy in the industry.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Contingent consideration payments to former equity holders of BlackThorn Therapeutics, including entities affiliated with ARCH Venture Partners.
• License and research collaboration agreements with Amgen Inc.

Stakeholder Impact

• Shareholders are requested to vote on director elections and executive compensation.
• Employees participate in the 401(k) plan and equity incentive programs.
• Creditors and partners are impacted by the ongoing collaboration and development milestones.

Next Steps

• Hold the Annual Meeting of Stockholders on May 27, 2026.
• Tabulate votes for the election of directors and advisory proposals.
• File a Form 8-K within four business days after the meeting to announce voting results.

Key Dates

Recommendation

The filing is a standard annual proxy statement. It does not contain material news that would significantly alter the investment thesis, suggesting a hold position for existing investors.

Keywords

Neumora Therapeutics, NMRA, Proxy Statement, Annual Meeting, Biotechnology, Executive Compensation, Corporate Governance